Nevertheless, central orexinergic system disruption through genetic or pharmacological manipulations that selectively target OX1R or OX2R results in opposite modulation of depression-like behavior (Scott et al. 2011). The gene discussed is HCRTR2; the disease is depressive symptom measurement.